Maurice Alexander, PharmD

University of North Carolina
Lineberger Comprehensive Cancer Center
Chapel Hill, NC
USA Papers:
681 Clinical Responses to CAR.CD30-T Cells in Patients with CD30+ Lymphomas Relapsed after Multiple Treatments Including Brentuximab Vedotin